eli lilly glp-1 agonist releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity GLP-1s & Beyond: Understanding Incretin

To date, it is the first drug approved by the Food and Drug Administration (FDA) developed specifically for the treatment of MASH

Missing meals, which results from significant appetite suppression, turns-off thyroid

This intelligent mechanism helps prevent blood sugar from dropping too low (hypoglycaemia)

The main challenge during the initial development of GLP-1 receptor agonists was the very short half-life in the circulation of 2 minutes [34]

Companies must evaluate whether to deepen investments in GLP-1 analog follow-ons, pivot towards innovative MoAs, or lead in combination therapies

Please consult a licensed healthcare provider before making any medical decisions